despit solid margin ep all-import tavr sale miss street
estim although result consist mgmt
expect adj tavr sale fell short consensu
move part includ remain german stock
lower neutral royalti revenu off-set stronger fx net
seem underli market growth still slower
investor expect result demonstr near
unpredict call quarter cours view quarter
make trend thesi aggreg tavr opportun
unchang share near all-tim high high bar
set investor expect stock afford miss wors
slightest doubt sustain market growth expect share
meaning under-perform morn trade maintain neutral
yet tavr pipelin updat encourag time expect
ultra launch consist last updat
eu/lat us management also confirm commenc
trial centera centera reportedli well-
receiv eu follow ce mark greater
contributor sale back half final approv low-risk cap
program allow continu penetr cohort though
limit program size like help overal sale much
tweak revenu estim trim tavr
forecast reflect miss rais surgic valv
critic estim momentum rais adj ep
forecast lower tax rate
valuat share trade ntm ep feel
current market cap reflect ew maintain lead share fulli
penetr tavr market given risk around viabil
true mitral platform find difficult argu meaning upsid
risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
adj ww thv revenu came consensu
expect lower model compani longer
break vs ou tavr perform dollar manag estim
 tavr grew mid-teen in-lin market ou tavr
procedur improv low double-digit lag overal market growth
result share shift compani point on-going
strength low volum center adopt well center addit
adj gross margin last year close
model y/i declin driven fx invest oper
exclud special adjust sg margin roughli
forecast result personnel-rel expens stronger
euro cost base meanwhil adj margin come
better estim driven higher thv program
invest adj ebit margin better forecast
lower tax rate vs estim ad anoth
revenu trim tavr forecast account
miss rais non-tavr segment estim net-net
result reduct revenu estim
maintain y/i growth rate
actualsbtig estimate variancethv valv revenu million adj ou heart valv revenu million adj consign revenu revenu expens expens net dilut gross margin bpssg margin bpsr spend bpsadj ebit margin bpstax rate bpssourc btig research estim compani filingsal metric present herein non-gaap basi margin estim non-gaap basi varianc
respect ep trim tax rate assumpt
follow revis expect offer manag incorpor
chang new adj ep forecast
edward rate neutral feel ew current market capit
price lead market share fulli penetr tavr market
ntm ep estim feel share least fairli price btig
provid price target neutral-r stock
risk rate includ competit patent litig slippag product
timelin chang procedur reimburs futur devic data
fda possibl multipl contraction/expans
exhibit comp tabl larg cap med-tech compani
newnewold sale growth incom ep growth btig research estim compani filingsntm johnsonjnjsel bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart y/i heart y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart y/i heart y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
